Owing to the severity of SSc, it is expected that the pan-lysyl oxidase inhibitor PXS-5505 may produce the desired high level of antifibrotic efficacy which LOXL2 antibody simtuzumab was lacking [19] while having better clinical tolerability compared to BAPN. Here, LOXL2 is linked to systemic sclerosis.